Submit

Login Login

Register Register

Home / Journals / BIOCELL / Online First / doi:10.32604/biocell.2024.055753
Journal Menu
Special Issues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

SAIB Annual Meetings

Open Access

REVIEW

Unraveling the RAGE axis in pulmonary disorders: Mechanisms and therapeutical potential

SHUOCHEN PANG1, TAO JIA1,*, ZIFENG YANG2,*
1 Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610041, China
2 National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China
* Corresponding Author: TAO JIA. Email: email; ZIFENG YANG. Email: email

BIOCELL https://doi.org/10.32604/biocell.2024.055753

Received 06 July 2024; Accepted 12 September 2024; Published online 05 October 2024

Abstract

The Receptor for Advanced Glycation End Products (RAGE) is a multiligand receptor of the immunoglobulin superfamily, notably highly expressed in the lungs. Its interaction with a variety of ligands, including advanced glycation end products (AGEs), S100 proteins, and high mobility group box 1 (HMGB1), activates multiple signaling pathways that are pivotal in the pathogenesis of numerous pulmonary diseases and comorbidities. However, comprehensive reviews on the role of ligands-RAGE signaling in specific lung diseases are rare. This review aims to elucidate the mechanisms by which RAGE-mediated signaling pathways either provide protective or pathogenic effects in pulmonary diseases, focusing on its key regulatory roles in asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), pulmonary fibrosis (PF), Lung Cancer and COVID-19 Pneumonia, as well as to discuss its therapeutic potential in the specific context of lung diseases.

Keywords

AGE; MAPK; NF-κB; RAGE ligands; Pulmonary diseases

  • 517

    View

  • 130

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link